Is Xocova (ensitrelvir) more effective than Paxlovid (nirmatrelvir plus ritonavir) for post‑exposure prophylaxis of COVID‑19 in individuals aged 12 years or older?

Xocova is Superior to Paxlovid for Post-Exposure Prophylaxis of COVID-19

Based on the most recent high-quality evidence, Xocova (ensitrelvir) should be used for post-exposure prophylaxis of COVID-19 in household contacts, as it is the only antiviral agent with proven efficacy for this specific indication, while Paxlovid (nirmatrelvir-ritonavir) has failed to demonstrate benefit in post-exposure prophylaxis trials.

FDA-Approved Indication

Xocova is FDA-approved specifically for post-exposure prophylaxis of COVID-19 in adults and adolescents ≥12 years following contact with an individual who has COVID-19 1. Paxlovid has no such approval and is only indicated for treatment of active COVID-19 infection.

Direct Evidence for Post-Exposure Prophylaxis

Xocova: Proven Efficacy

The SCORPIO-PEP trial (2026) demonstrated that ensitrelvir significantly reduced COVID-19 incidence in household contacts 2:

• COVID-19 incidence: 2.9% with ensitrelvir vs. 9.0% with placebo
• Risk ratio: 0.33 (95% CI 0.22-0.49; P<0.001) - representing a 67% risk reduction
• Administered within 72 hours of index patient symptom onset
• Similar adverse event rates to placebo (15.1% vs. 15.5%)
• No COVID-19-related hospitalizations or deaths

Paxlovid: Failed to Show Benefit

A phase 2-3 trial (2024) of nirmatrelvir-ritonavir for post-exposure prophylaxis showed no significant benefit 3:

• Symptomatic SARS-CoV-2 infection: 2.6% (5-day), 2.4% (10-day) vs. 3.9% (placebo)
• Risk reduction: 29.8% (P=0.17) for 5-day and 35.5% (P=0.12) for 10-day regimens - neither statistically significant
• The trial failed to meet its primary endpoint

Dosing and Administration

For Xocova (post-exposure prophylaxis):

• 375 mg (three 125-mg tablets) on Day 1
• 125 mg (one tablet) daily on Days 2-5
• Begin within 72 hours of contact with COVID-19 positive individual 1
• Can be taken with or without food

For Paxlovid (treatment only, not prophylaxis):

• 300 mg nirmatrelvir/100 mg ritonavir every 12 hours for 5 days
• Only for treatment of active infection, not prevention

Comparative Antiviral Activity

While both drugs target the SARS-CoV-2 main protease, head-to-head comparison in treatment (not prophylaxis) showed 4:

• Viral clearance half-life: 5.9 hours with ensitrelvir vs. 5.2 hours with nirmatrelvir
• Ensitrelvir clearance was 16% slower than nirmatrelvir but still 82% faster than no treatment
• Both drugs showed similar viral rebound rates (7% vs. 5%)

Important Safety Considerations

Xocova-Specific Warnings

• Embryofetal toxicity: Verify pregnancy status before initiating; use effective contraception during treatment and for 2 weeks after 1
• Strong CYP3A inhibitor with significant drug interactions
• Contraindicated with drugs primarily metabolized by CYP3A and strong CYP3A inducers

Paxlovid Drug Interactions

• Ritonavir causes extensive drug-drug interactions that may be more complex to manage 5
• Requires careful medication review and potential dose adjustments

Clinical Algorithm for Post-Exposure Prophylaxis

When a household contact is exposed to COVID-19:

1. Verify eligibility: Age ≥12 years, negative SARS-CoV-2 test, within 72 hours of index patient symptom onset
2. For females of reproductive potential: Verify negative pregnancy test before initiating Xocova
3. Review contraindications: Check for CYP3A-metabolized drugs and strong CYP3A inducers
4. Initiate Xocova: 375 mg Day 1, then 125 mg Days 2-5
5. Counsel on contraception: Effective contraception during treatment and 2 weeks after

Paxlovid should not be used for post-exposure prophylaxis given the lack of demonstrated efficacy in this setting 3.

Guideline Context

WHO guidelines strongly recommend nirmatrelvir-ritonavir for treatment of non-severe COVID-19 in high-risk patients 5, but these recommendations do not address post-exposure prophylaxis. The guidelines note significant uncertainties regarding efficacy in specific subgroups and lack of data for prophylactic use.

Key Pitfalls to Avoid

• Do not confuse treatment with prophylaxis: Paxlovid is effective for treating active COVID-19 but has failed in prevention trials
• Do not delay Xocova initiation: Must begin within 72 hours of exposure for optimal efficacy
• Do not overlook pregnancy screening: Mandatory before starting Xocova due to embryofetal toxicity risk
• Do not ignore drug interactions: Both agents have significant CYP3A interactions requiring careful medication review